AU2002249197A1 - 1g(a)-amino-n-hydroxy-acetamide derivatives - Google Patents

1g(a)-amino-n-hydroxy-acetamide derivatives

Info

Publication number
AU2002249197A1
AU2002249197A1 AU2002249197A AU2002249197A AU2002249197A1 AU 2002249197 A1 AU2002249197 A1 AU 2002249197A1 AU 2002249197 A AU2002249197 A AU 2002249197A AU 2002249197 A AU2002249197 A AU 2002249197A AU 2002249197 A1 AU2002249197 A1 AU 2002249197A1
Authority
AU
Australia
Prior art keywords
hydroxy
amino
acetamide derivatives
acetamide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002249197A
Other languages
English (en)
Inventor
Kenji Hayakawa
Genji Iwasaki
Shinichi Koizumi
Ichiro Umemura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Original Assignee
Novartis Pharma GmbH Austria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria filed Critical Novartis Pharma GmbH Austria
Publication of AU2002249197A1 publication Critical patent/AU2002249197A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2002249197A 2001-02-09 2002-02-08 1g(a)-amino-n-hydroxy-acetamide derivatives Abandoned AU2002249197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0103303.4 2001-02-09
GBGB0103303.4A GB0103303D0 (en) 2001-02-09 2001-02-09 Organic compounds
PCT/EP2002/001345 WO2002064552A1 (en) 2001-02-09 2002-02-08 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES

Publications (1)

Publication Number Publication Date
AU2002249197A1 true AU2002249197A1 (en) 2002-08-28

Family

ID=9908475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002249197A Abandoned AU2002249197A1 (en) 2001-02-09 2002-02-08 1g(a)-amino-n-hydroxy-acetamide derivatives

Country Status (10)

Country Link
US (3) US7112611B2 (enExample)
EP (1) EP1360175A1 (enExample)
JP (1) JP4262982B2 (enExample)
CN (1) CN100509773C (enExample)
AR (1) AR032553A1 (enExample)
AU (1) AU2002249197A1 (enExample)
CA (1) CA2435611C (enExample)
GB (1) GB0103303D0 (enExample)
PE (1) PE20020845A1 (enExample)
WO (1) WO2002064552A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
CN101410370B (zh) * 2006-03-29 2013-06-12 诺瓦提斯公司 基于异羟肟酸酯的选择性mmp抑制剂
US20100234378A1 (en) * 2006-08-22 2010-09-16 Array Biopharma Inc. Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
EP3973967A1 (en) 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US20180353174A1 (en) * 2017-06-13 2018-12-13 Ethicon Llc Surgical Stapler with Controlled Healing
US11058804B2 (en) 2017-06-13 2021-07-13 Ethicon Llc Surgical fastener device for the prevention of ECM degradation
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器
JP2020523132A (ja) * 2017-06-13 2020-08-06 エシコン エルエルシーＥｔｈｉｃｏｎ ＬＬＣ 広域スペクトルｍｍｐ阻害剤を有する手術用締結具
US10939911B2 (en) 2017-06-13 2021-03-09 Ethicon Llc Surgical stapler with end effector coating

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2513826A (en) * 1946-12-05 1950-07-04 Gen Aniline & Film Corp Aromatic sulfonhydrazides
US4772733A (en) 1986-07-17 1988-09-20 Hercules Incorporated Epoxy-azides
US4806528A (en) * 1987-09-04 1989-02-21 Hanreich Reinhard G Process for the preparation of 2-(2-chloroethoxy)-benzenesulfonamide
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2682498A1 (fr) * 1991-10-15 1993-04-16 Kodak Pathe Colorants comprenant des macrocycles thioethers.
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
GB9503749D0 (en) * 1995-02-24 1995-04-12 British Biotech Pharm Synthesis of hydroxamic acid derivatives
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
CN100413859C (zh) * 1996-01-23 2008-08-27 盐野义制药株式会社 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂
EE03965B1 (et) 1996-05-17 2003-02-17 Warner-Lambert Company Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid
WO1997045402A1 (fr) 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Derives de phenylsulfonamide
US6541276B2 (en) 1996-10-28 2003-04-01 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives and combinatorial libraries thereof
KR20000057444A (ko) 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 심기능부전 및 심실확장의 치료 및 예방 방법
IL131042A0 (en) 1997-02-03 2001-01-28 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives
GB9708133D0 (en) 1997-04-22 1997-06-11 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
BR9810841A (pt) 1997-07-31 2001-07-10 Procter & Gamble Inibidores de metaloprotease alicìclicos
IL127496A0 (en) 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
EP1918278A1 (en) 1998-02-04 2008-05-07 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JPH11236369A (ja) 1998-02-23 1999-08-31 Kotobuki Seiyaku Kk スルホンアミド誘導体及びその製造法並びにこれを含有する医薬組成物
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
CA2355902A1 (en) 1998-12-22 2000-06-29 F. Hoffmann-La Roche Ag Sulfonamide hydroxamates
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7659293B2 (en) 2010-02-09
AR032553A1 (es) 2003-11-12
CA2435611C (en) 2011-07-12
PE20020845A1 (es) 2002-10-30
CN1525956A (zh) 2004-09-01
CA2435611A1 (en) 2002-08-22
GB0103303D0 (en) 2001-03-28
JP4262982B2 (ja) 2009-05-13
US7112611B2 (en) 2006-09-26
US20060270719A1 (en) 2006-11-30
CN100509773C (zh) 2009-07-08
WO2002064552A1 (en) 2002-08-22
US20040082630A1 (en) 2004-04-29
US7291634B2 (en) 2007-11-06
WO2002064552A8 (en) 2002-12-12
EP1360175A1 (en) 2003-11-12
US20080176916A1 (en) 2008-07-24
JP2004523545A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
AU2002349676A1 (en) 4-oxoquinoline derivatives
AUPR748801A0 (en) A stent
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2002249197A1 (en) 1g(a)-amino-n-hydroxy-acetamide derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AUPQ837500A0 (en) A mounting
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2002363600A1 (en) Novel phenyl-propargylether derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002358715A1 (en) Tetrahydrobenzfluorene derivatives
AU2002366300A1 (en) A phantom
AU2002359571A1 (en) A softening-through-the-wash composition
AU2001241084A1 (en) Imidazolylbenzophenone derivatives
AU2002353185A1 (en) A mounting
AU2002255269B8 (en) 2-Iminopyrrolidine derivatives
AU2001242799A1 (en) Zofimarin derivatives
AUPR521101A0 (en) A method - iii
AUPR520801A0 (en) A method - II
AU2002311722A1 (en) A lung-ventilating arrangement
AU2002221445A1 (en) A simple igniter
AU2002302578A1 (en) Amido-diphenyl derivatives
AU2002249205A1 (en) Bis-triazinylaminobenzoxazole derivatives
HK1062431A (en) A-amino-n-hydroxy-acetamide derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase